MedTrace Logo

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

NCT01546818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2013-09-09

No results posted yet for this study

Summary

The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

SAV001-H

A whole-killed HIV

Sponsors & Collaborators

  • Sumagen

    lead INDUSTRY

Principal Investigators

  • Anthony M Mills, M.D. · Anthony Mills MD Inc

  • Stefan Schneider, M.D. · Living Hope Clinical Foundation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-03-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01546818 on ClinicalTrials.gov